Kingdon Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Kingdon Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200,000	Closed	-$23.7M	–	104
2022 Q1	$23.7M	Hold	200,000	–	–	2.47%	11
2021 Q4	$27.6M	Buy	+200,000	New	+$25.4M	3.17%	6
2021 Q1	–	Sell	-150,000	Closed	-$12.9M	–	82
2020 Q4	$12.9M	Buy	+150,000	New	+$12.7M	1.39%	20
2020 Q3	–	Sell	-100,000	Closed	-$7.31M	–	74
2020 Q2	$7.31M	Buy	+100,000	New	+$5.32M	0.67%	38
2020 Q1	–	Sell	-300	Closed	-$16K	–	72
2019 Q4	$16K	Sell	300 -99,700	-100%	-$4.94M	﹤0.01%	55
2019 Q3	$4.17M	Buy	+100,000	New	+$4.22M	0.49%	48
2019 Q2	–	Sell	-100,000	Closed	-$5.15M	–	92
2019 Q1	$5.15M	Buy	+100,000	New	+$4.32M	0.69%	43

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kingdon Capital Management's BHVN Position: Q2 2022 in Review

Kingdon Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 136,306 shares — an estimated $16.2M sold.

Kingdon Capital Management first reported a position in BHVN in Q1 2018 and held it in 17 quarters. The position peaked at $105M in Q4 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Kingdon Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Kingdon Capital Management sold 136,306 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $16.2M.
Kingdon Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 17 quarters.
Kingdon Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $105M in Q4 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Kingdon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.